Twist Bioscience holder plans sale of 2,184 shares

Twist Bioscience received a notice that a holder plans to sell 2,184 shares of its common stock on or about 02/13/2026.

Rhea-AI Filing Summary

Twist Bioscience received a notice that a holder plans to sell 2,184 shares of its common stock on or about 02/13/2026. The shares, with an aggregate market value of $105,401.37, will be sold through Fidelity Brokerage Services LLC on the NASDAQ exchange.

The securities were acquired on 02/05/2026 via restricted stock vesting from the issuer as compensation. As of the filing, there were 61,311,704 common shares outstanding, which is a baseline figure and not the amount being sold.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stock sale is disclosed in the TWST Form 144 filing?

The filing discloses a planned sale of 2,184 shares of Twist Bioscience common stock. The shares have an aggregate market value of $105,401.37 and are expected to be sold on or about 02/13/2026 through Fidelity on NASDAQ.

How were the Twist Bioscience (TWST) shares being sold acquired?

The 2,184 Twist Bioscience shares were acquired on 02/05/2026 through restricted stock vesting. They were obtained directly from the issuer as compensation, rather than purchased in the open market, and then scheduled for resale under Rule 144.

What is the market value of the TWST shares covered by this Form 144?

The planned sale covers Twist Bioscience common stock with an aggregate market value of $105,401.37. This value is based on the 2,184 shares to be sold, as disclosed in the securities information section of the Form 144 notice.

On which exchange and through which broker will the TWST shares be sold?

The 2,184 Twist Bioscience shares are planned to be sold on the NASDAQ stock exchange. The filing lists Fidelity Brokerage Services LLC, located in Smithfield, Rhode Island, as the broker handling the transaction for the selling holder.

How many Twist Bioscience (TWST) shares were outstanding when the Form 144 was filed?

The notice reports 61,311,704 Twist Bioscience common shares outstanding. This figure provides context for the size of the 2,184-share planned sale but is a baseline capital structure number, not the quantity being sold under this Form 144.

What does the representation about material adverse information in the TWST Form 144 mean?

By signing the notice, the selling holder represents they do not know any material adverse information about Twist Bioscience’s current or prospective operations that has not been publicly disclosed, as required for sales made in reliance on Rule 144.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/13/2026 - 03:17 PM EST Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001227886
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Twist Bioscience Corp
SEC File Number	001-38720
Address of Issuer	681 GATEWAY BLVD. SOUTH SAN FRANCISCO CALIFORNIA 94080
Phone	800-719-0671
Name of Person for Whose Account the Securities are To Be Sold	CHESS ROBERT
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	2184	105401.37	61311704	02/13/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/05/2026	Restricted Stock Vesting	Issuer			2184	02/05/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	Sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution.
Date of Notice	02/13/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Daniel Tucci, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Robert Chess
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)